Results 11 to 20 of about 790 (114)

COMPARISON OF THE METABOLIC EFFECTS OF CARVEDILOL AND METОPROLOL IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT AND OBESITY. THE CAMELLIA TRIAL

Рациональная фармакотерапия в кардиологии, 2016
Aim. To compare two therapies based on carvedilol or metoprolol in hypertensive patients with overweight and obesity.Material and methods. 320 patients with arterial hypertension (1-2 degree) were involved in the study.
S. Y. Martsevich, N. P. Kutishenko, E. V. Shilova, A. D. Deev, S. A. Shalnova, R. G. Oganov, I. A. Veliganina, E. G. Volkova, Yu. E. Voskanjan, L. I. Gapon, P Ya. Dovgalevskij, V. Ya. Ermolina, E. M. Idrisova, N. N. Ilov, A. R. Kiselev, S. Yu. Levashov, V. A. Nevzorova, G. I. Nechaeva, T. N. Panova, I. I. Reznik, V. V. Skibickij, L. A. Sokolova, V. P. Terentev, N. V. Hailo, A. V. Shabalin, T. V. Shnjukova, V. V. Yakusevich   +26 more
doaj   +3 more sources

Carvedilol

New England Journal of Medicine, 1999
Carvedilol is the first beta-blocker to obtain approval for treatment of heart failure. Improvement in hemodynamic parameters was initially documented in three methodologically sound studies involving 156 patients. Follow up was limited to 16 weeks. A placebo-controlled, double-blind trial involving 1094 patients showed beneficial effects on overall ...
  +7 more sources

In vitro and in silico study on the effect of carvedilol and sorafenib alone and in combination on the growth and inflammatory response of melanoma cells

Saudi Pharmaceutical Journal, 2023
Melanoma is an aggressive skin cancer. Increasing evidence has shown the role of β-adrenergic receptors in the pathogenesis of melanoma. Carvedilol is a widely used non-selective β-AR antagonist with potential anticancer activity.
Joanna Wawszczyk, Radosław Wolan, Sławomir Smolik, Małgorzata Kapral   +3 more
doaj   +1 more source

Solubility enhancement of carvedilol by multicomponent crystal approach using glycine and arginine as coformers [PDF]

Pharmacia, 2023
A Carvedilol is a member of BCS class II, it has a low solubility and bioavailability. This work intends to increase the solubility of carvedilol using a multicomponent crystal method.
Iyan Sopyan, Wuri Ariestika Sari, Sandra Megantara, Taofik Rusdiana   +3 more
doaj   +3 more sources

The Potential Benefits of Using Garlic Oil and Its Active Constituent, Dially Disulphide, in Combination With Carvedilol in Ameliorating Isoprenaline-Induced Cardiac Damage in Rats

Frontiers in Pharmacology, 2021
Garlic oil and its primary component, diallyl disulphide (DADS), were tested in rats with isoprenaline (ISO) induced myocardial infarction for cardioprotective benefits when combined with carvedilol.
Syed Mohammed Basheeruddin Asdaq, Obulesu Challa, Abdulhakeem S. Alamri, Abdulhakeem S. Alamri, Walaa F. Alsanie, Walaa F. Alsanie, Majid Alhomrani, Majid Alhomrani, Mohammed Asad   +8 more
doaj   +1 more source

PHARMACOECONOMIC ANALYSIS OF CARVEDILOL THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC RISK FACTORS (ACCORDING TO THE CAMELLIA STUDY)

Рациональная фармакотерапия в кардиологии, 2016
Aim. To perform cost-effectiveness analysis of 24 weeks antihypertensive therapy based on carvedilol or metoprolol in patients with arterial hypertension (HT) 1-2 degrees and overweight/obesity. To assess effects of carvedilol therapy on 10-year expected
S. Y. Martsevich, N. P. Kutishenko, A. D. Deev, S. A. Shalnova, R. G. Oganov   +4 more
doaj   +1 more source

Development of Carvedilol-Loaded Albumin-Based Nanoparticles with Factorial Design to Optimize In Vitro and In Vivo Performance

Pharmaceutics, 2023
Carvedilol, an anti-hypertensive medication commonly prescribed by healthcare providers, falls under the BCS class II category due to its low-solubility and high-permeability characteristics, resulting in limited dissolution and low absorption when taken
Mohamed S. Attia, Mohamed F. Radwan, Tarek S. Ibrahim, Tarek M. Ibrahim   +3 more
doaj   +1 more source

Assessment of clinical effect and treatment quality of immediate-release carvedilol-IR versus SLOW release carvedilol-SR in Heart Failure patients (SLOW-HF): study protocol for a randomized controlled trial

Trials, 2018
Background Carvedilol is a non-selective, third-generation beta-blocker and is one of the cornerstones for treatment for patients with heart failure and reduced ejection fraction (HFrEF). However, due to its short half-life, immediate-release carvedilol (
Dong-Ju Choi, Chan Soon Park, Jin Joo Park, Hae-Young Lee, Seok-Min Kang, Byung-Su Yoo, Eun-Seok Jeon, Seok Keun Hong, Joon-Han Shin, Myung-A Kim, Dae-Gyun Park, Eung-Ju Kim, Soon-Jun Hong, Seok Yeon Kim, Jae-Joong Kim   +14 more
doaj   +1 more source

Differential effects of adrenergic antagonists (Carvedilol vs Metoprolol) on parasympathetic and sympathetic activity: a comparison of clinical results

Heart International, 2014
Background Cardiovascular autonomic neuropathy (CAN) is recognized as a significant health risk, correlating with risk of heart disease, silent myocardial ischemia or sudden cardiac death.
Heather L. Bloom, Aaron I. Vinik, Joe Colombo   +2 more
doaj   +1 more source

Evaluation of Carvedilol in Prevention of First Attack of Variceal Hemorrhage in Patients with Liver Cirrhosis [PDF]

Afro-Egyptian Journal of Infectious and Endemic Diseases, 2012
Background and study aim: Carvedilol has beneficial effects on splanchnic haemodynamics following acute and chronic administration in cirrhosis. The aim of this study is to evaluate the role of carvedilol in prevention of first variceal bleeding in ...
Hosam Dawod, Eman Abdel Aal, Samy Essa, Ahmad Mahmod   +3 more
doaj   +1 more source